Logo image of BBNX

BETA BIONICS INC (BBNX) Stock Fundamental Analysis

NASDAQ:BBNX - Nasdaq - US08659B1026 - Common Stock - Currency: USD

10.96  -0.1 (-0.9%)

After market: 10.96 0 (0%)

Fundamental Rating

3

Overall BBNX gets a fundamental rating of 3 out of 10. We evaluated BBNX against 191 industry peers in the Health Care Equipment & Supplies industry. BBNX has a great financial health rating, but its profitability evaluates not so good. BBNX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BBNX had negative earnings in the past year.
In the past year BBNX has reported a negative cash flow from operations.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BBNX's Return On Assets of -36.59% is on the low side compared to the rest of the industry. BBNX is outperformed by 60.21% of its industry peers.
Looking at the Return On Equity, with a value of -72.04%, BBNX is in line with its industry, outperforming 42.41% of the companies in the same industry.
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROIC N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 55.11%, BBNX perfoms like the industry average, outperforming 47.64% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for BBNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

7

2. Health

2.1 Basic Checks

BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BBNX has about the same amount of shares outstanding.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of 1.43, we must say that BBNX is in the distress zone and has some risk of bankruptcy.
BBNX's Altman-Z score of 1.43 is in line compared to the rest of the industry. BBNX outperforms 57.07% of its industry peers.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.43
ROIC/WACCN/A
WACC9.07%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

BBNX has a Current Ratio of 6.29. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.29, BBNX belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
BBNX has a Quick Ratio of 5.66. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BBNX (5.66) is better than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 6.29
Quick Ratio 5.66
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BBNX have decreased strongly by -24.17% in the last year.
Looking at the last year, BBNX shows a very strong growth in Revenue. The Revenue has grown by 442.93%.
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%

3.2 Future

BBNX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.90% yearly.
The Revenue is expected to grow by 32.29% on average over the next years. This is a very strong growth
EPS Next Y11.87%
EPS Next 2Y3.04%
EPS Next 3Y0.9%
EPS Next 5YN/A
Revenue Next Year27.44%
Revenue Next 2Y31.13%
Revenue Next 3Y32.29%
Revenue Next 5YN/A

3.3 Evolution

BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 50M 100M 150M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.04%
EPS Next 3Y0.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BETA BIONICS INC

NASDAQ:BBNX (4/25/2025, 8:00:01 PM)

After market: 10.96 0 (0%)

10.96

-0.1 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-06 2025-05-06
Inst Owners57.77%
Inst Owner ChangeN/A
Ins Owners6.74%
Ins Owner Change99.12%
Market Cap475.12M
Analysts86.15
Price Target26.23 (139.32%)
Short Float %7.74%
Short Ratio6.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.7%
PT rev (3m)N/A
EPS NQ rev (1m)-11.43%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-12.73%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-3.94%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.84%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.3
P/FCF N/A
P/OCF N/A
P/B 6.25
P/tB 6.25
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.5
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.11%
FCFM N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 148.71%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.29
Quick Ratio 5.66
Altman-Z 1.43
F-Score5
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)68.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)146.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
EPS Next Y11.87%
EPS Next 2Y3.04%
EPS Next 3Y0.9%
EPS Next 5YN/A
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%
Revenue Next Year27.44%
Revenue Next 2Y31.13%
Revenue Next 3Y32.29%
Revenue Next 5YN/A
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.14%
EBIT Next 3Y-18.79%
EBIT Next 5YN/A
FCF growth 1Y-57.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.78%
OCF growth 3YN/A
OCF growth 5YN/A